Your browser doesn't support javascript.
loading
The effects of low-dose radiation therapy in patients with mild-to-moderate Alzheimer's dementia: an interim analysis of a pilot study.
Kim, Aryun; Lee, Jeonghwan; Moon, Hansol; Kim, Chulhan; Yoo, Min Young; Park, Woo Yoon; Kim, Won Dong; Seo, Young-Seok.
Afiliación
  • Kim A; Department of Neurology, Chungbuk National University Hospital, Cheongju, Korea.
  • Lee J; Department of Psychiatry, Chungbuk National University Hospital, Cheongju, Korea.
  • Moon H; Department of Nuclear Medicine, Chungbuk National University Hospital, Cheongju, Korea.
  • Kim C; Department of Nuclear Medicine, Chungbuk National University Hospital, Cheongju, Korea.
  • Yoo MY; Department of Nuclear Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.
  • Park WY; Department of Radiation Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
  • Kim WD; Department of Radiation Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
  • Seo YS; Department of Radiation Oncology, Chungbuk National University Hospital, Cheongju, Korea.
Radiat Oncol J ; 41(2): 89-97, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37403351
ABSTRACT

PURPOSE:

We aimed to determine whether low-dose radiotherapy (LDRT) is effective in patients with Alzheimer disease (AD). MATERIALS AND

METHODS:

We included patients according to the following criteria probable Alzheimer's dementia according to the New Diagnostic Criteria for Alzheimer's Disease; confirmation of amyloid plaque deposits on baseline amyloid positron emission tomography (PET); a Korean Mini-Mental State Examination 2nd edition (K-MMSE-2) score of 13-26; and a Global Clinical Dementia Rating (CDR) score of 0.5-2 points. LDRT was performed six times at 0.5 Gy each. Post-treatment cognitive function tests and PET-CT examinations were performed to evaluate efficacy. The medication for AD treatment was maintained throughout the study period.

RESULTS:

At 6 months after LDRT, neurological improvement was seen in 20% of patients. Patient #2 showed improvement in all domains of the Seoul Neuropsychological Screening Battery II (SNSB-II). Moreover, the K-MMSE-2 and Geriatric Depression Score-Short Form scores improved from 20 to 23 and from 8 to 2, respectively. For patient #3, the CDR score (sum of box score) improved from 1 (4.0) to 1 (3.5) at 3 months follow-up. Moreover, the Z scores for language and related functions, memory, and frontal executive function improved to -2.56, -1.86, and -1.32, respectively at the 6-month follow-up. Two patients complained of mild nausea and mild hair loss during LDRT, which improved after treatment.

CONCLUSION:

One of the five patients with AD treated with LDRT experienced a temporary improvement in SNSB-II. LDRT is tolerable in patients with AD. We are currently under follow-up and will conduct cognitive function tests after 12 months after LDRT. A large-scale randomized controlled trial with a longer follow-up period is warranted to determine the effect of LDRT on patients with AD.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Radiat Oncol J Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Radiat Oncol J Año: 2023 Tipo del documento: Article